IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer


Kargi A., Yalcin A. D. , ERİN N., Savas B., Polat H. H. , Gorczynski R. M.

CLINICAL LABORATORY, vol.58, pp.501-505, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 58
  • Publication Date: 2012
  • Title of Journal : CLINICAL LABORATORY
  • Page Numbers: pp.501-505

Abstract

Background: Colorectal cancer is the third most common human cancer and the third leading cause of cancer related death. BevacizumAb is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancers.